Mesoglycan for Acute Hemorrhoidal Disease

Launched by SOCIETA ITALIANA DI CHIRURGIA COLORETTALE · Oct 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Mesoglycan for people suffering from hemorrhoids, which are swollen blood vessels in the rectal area that can cause symptoms like painless rectal bleeding. The goal is to see if Mesoglycan can effectively reduce the symptoms of hemorrhoidal disease and improve patients' quality of life compared to a placebo (a substance with no active ingredients). Hemorrhoids are common, especially in adults aged 45 to 65, and the trial aims to provide more information on how Mesoglycan can help.

To be eligible for this trial, participants need to have a diagnosis of mild to moderate hemorrhoids or an external hemorrhoidal thrombosis (a painful condition due to a clot). Women who could become pregnant must have a negative pregnancy test and understand the trial's details. Participants will be given either Mesoglycan or a placebo and monitored for their symptoms and overall well-being. It's important to note that individuals with blood clotting disorders, those undergoing specific cancer treatments, or those taking blood thinners cannot participate in the trial. This study is not yet recruiting, so those interested should keep an eye out for further updates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of grade I-III hemorrhoidal disease classified according to Goligher classification or diagnosis of external hemorrhoid thrombosis
• • Female patients of childbearing age with a negative pregnancy test
• • Patients able to understand informed consent
• • Signed Informed Consent.
• Exclusion Criteria:
• • Blood coagulations disorders
• • Patients undergoing chemoradiation
• • intake of anticoagulants
• • pregnancy